ArticleScientific reports2016
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it, 174 citations in OpenAlex.
- MetaDCN: meta-analysis framework for differential co-expression network detection with an application in breast cancer.Bioinformatics (Oxford, England) · 2017Pooled it
- PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.Nature cancer · 2023Trial
- GELATO - a clinical trial specific for patients with lobular breast cancer.Nature cancer · 2023Trial
- Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.Breast cancer research and treatment · 2022Trial
- Toward targeted therapeutics for lobular breast cancer.The Journal of clinical investigation · 2026Review
- FastMI-HGNet: A Two-Stream Heterogeneous Graph Neural Network for Multi-Omics Disease Classification.Genes · 2026Article
- Identification and credentialing of patient-derived xenograft models of invasive lobular carcinoma.Disease models & mechanisms · 2026Article
- Estrogen receptor-positive cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma.bioRxiv : the preprint server for biology · 2026Article
- Invasive Lobular Carcinoma Has Higher Immune Response Than Invasive Ductal Carcinoma in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers.World journal of oncology · 2025Article
- Emerging Biomarkers to Predict Immunotherapy Response in Breast Cancer.Current oncology reports · 2025Review
- Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database.Breast cancer research and treatment · 2025Article
- Cancer-associated fibroblast driven paracrine IL-6/STAT3 signaling promotes migration and dissemination in invasive lobular carcinoma.Breast cancer research : BCR · 2025Article
- Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast.Breast cancer (Tokyo, Japan) · 2025Article
- Afadin loss induces breast cancer metastasis through destabilisation of E-cadherin to F-actin linkage.The Journal of pathology · 2025Article
- Proteomics in Diagnostic Evaluation and Treatment of Breast Cancer: A Scoping Review.Journal of personalized medicine · 2025Review
- A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.NPJ breast cancer · 2025Article
- Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights.Clinical Medicine Insights. Oncology · 2025Review
- Pan-cancer analyses identify oncogenic drivers, expression signatures, and therapeutic vulnerabilities in RHO GTPase pathway genes.Frontiers in bioinformatics · 2025Article
- Immune infiltration correlates with transcriptomic subtypes in primary estrogen receptor positive invasive lobular breast cancer.NPJ precision oncology · 2024Article
- Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.Molecular oncology · 2024Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 14 institutions in 7 countries.
Funding
Abstract
Invasive lobular carcinoma (ILC) is the second most frequently occurring histological breast cancer subtype after invasive ductal carcinoma (IDC), accounting for around 10% of all breast cancers. The molecular processes that drive the development of ILC are still largely unknown. We have performed a comprehensive genomic, transcriptomic and proteomic analysis of a large ILC patient cohort and present here an integrated molecular portrait of ILC. Mutations in CDH1 and in the PI3K pathway are the most frequent molecular alterations in ILC. We identified two main subtypes of ILCs: (i) an immune related subtype with mRNA up-regulation of PD-L1, PD-1 and CTLA-4 and greater sensitivity to DNA-damaging agents in representative cell line models; (ii) a hormone related subtype, associated with Epithelial to Mesenchymal Transition (EMT), and gain of chromosomes 1q and 8q and loss of chromosome 11q. Using the somatic mutation rate and eIF4B protein level, we identified three groups with different clinical outcomes, including a group with extremely good prognosis. We provide a comprehensive overview of the molecular alterations driving ILC and have explored links with therapy response. This molecular characterization may help to tailor treatment of ILC through the application of specific targeted, chemo- and/or immune-therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.